Tricalcium phosphate and osteogenin: a bioactive onlay bone graft substitute

Autogenous bone grafts remain the gold standard in bone regeneration but are limited by donor site morbidity and limited availability. These drawbacks have driven research into alternative graft materials that can mimic biological and structural functions. It was already known that tricalcium phosphate, a biodegradable ceramic, can serve as a scaffold for new bone growth. However, the rate of integration and resorption has been a persistent challenge. This gap motivated investigations into combining tricalcium phosphate with osteoinductive proteins like osteogenin. Prior research has shown that osteogenin can stimulate osteoblast differentiation and bone formation. No prior work had resolved how this combination performs in a controlled onlay graft setting. This paper addresses the need for a graft material that supports bone growth while maintaining structural integrity over time. The study introduces a novel approach by evaluating a composite material in a preclinical model.

The aim of this research was to assess the effectiveness of a tricalcium phosphate and osteogenin composite as an onlay bone graft substitute. The specific problem addressed is the lack of reliable, biologically active graft materials that can replace autografts. The motivation stems from the clinical limitations of current grafting techniques. The study sought to determine whether adding osteogenin to tricalcium phosphate would enhance bone formation and integration. The model used is a rabbit calvarial implant system, which allows for controlled observation of graft behavior. The researchers aimed to evaluate bone ingrowth, tricalcium phosphate resorption, and tissue maturation over time. The study also aimed to compare outcomes between treated and untreated implants. The ultimate goal was to identify a graft material that could maintain volume while promoting new bone growth.

The study utilized a rabbit calvarial model to evaluate the tricalcium phosphate/osteogenin composite. Fourteen New Zealand White rabbits received implants on the frontal bone, with each implant measuring 15 mm in diameter and 5 mm in thickness. The implants had a pore size of 100–200 microns. The experimental group received implants supplemented with 185 micrograms of osteogenin, while the control group received implants without the protein. Implants were harvested at 1, 3, and 6 months post-implantation. Histological analysis using hematoxylin and eosin staining was performed to assess tissue composition. Microradiography was used to evaluate mineral density and tricalcium phosphate resorption. Scanning electron microscopy with backscatter imaging was employed to analyze bone structure and marrow differentiation. The data were compared between the two groups to determine the effect of osteogenin on bone formation and graft integration.

At one month, both groups showed minimal bone ingrowth and limited tricalcium phosphate resorption. By three months, the osteogenin-treated implants demonstrated a modest increase in bone ingrowth (8.85%) compared to controls (5.87%). Tricalcium phosphate resorption was also slightly higher in the experimental group (32.86%) than in controls (37.08%). At six months, the differences became statistically significant. The experimental group showed 22.33% bone ingrowth versus 6.96% in controls (p = 0.000). Tricalcium phosphate resorption was 27.25% in the experimental group versus 37.80% in controls (p = 0.004). Histological analysis revealed that control implants contained mostly woven bone at six months. In contrast, osteogenin-treated implants had predominantly mature lamellar bone with well-differentiated marrow. Both groups maintained original implant volume across all time points. These findings suggest that osteogenin enhances bone formation and tissue maturation.

The authors propose that the tricalcium phosphate/osteogenin composite may be a viable onlay bone graft substitute. The findings suggest that osteogenin significantly enhances bone ingrowth and tissue maturation compared to tricalcium phosphate alone. The composite maintained its volume throughout the study period, which is a key advantage for clinical applications. The results indicate that osteogenin-treated implants promote the formation of mature lamellar bone rather than woven bone. The study supports the hypothesis that adding osteogenin improves the biological performance of tricalcium phosphate. The authors suggest that this material could be used in clinical settings where autografts are not feasible. The findings highlight the potential of combining resorbable ceramics with osteoinductive proteins. The study concludes that the composite material may offer a reliable alternative to traditional grafting methods.